Navigation Links
Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
Date:2/15/2008

- Webcast on February 21st at 12:00 p.m. Pacific Time -

MONTVALE, N.J., Feb. 15 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) announced today that Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista will present at the Roth 20th Annual OC Growth Stock Conference on Thursday, February 21, 2008 at 12:00 p.m. Pacific time (3:00 p.m. Eastern time) at the Ritz Carlton Hotel in Laguna Niguel, California. The conference is being held from February 19-21, 2008.

Dr. Berkowitz will give an overview of the company's planned and/or ongoing Phase 2 initiatives for ALT-2074 in cardiovascular diseases and psoriasis, and alagebrium in heart failure and diabetic nephropathy. He will also provide an update of recent milestones.

The presentation will be available to the general public via a live webcast by Roth at http://www.roth.com. The presentation will be simultaneously webcast and can be viewed live on the investor relations section of the Company's website at http://www.synvista.com. Participants are encouraged to log on to the webcast approximately 5 to 10 minutes prior to the start of the presentation. It will be archived there after the event.

Note: Synvista is available for one-on-one meetings on February 20th and 21st. Please contact Jeff Kelley of Lippert/Heilshorn & Associates at 310-691-7100 or jkelley@LHAI.com, to reserve a meeting time.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropath
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing
3. Transition Therapeutics Announces Second Quarter Fiscal 2008 Financial Results
4. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
5. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
6. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST
7. Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
8. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
9. Prime Therapeutics Becomes First PBM to Join the Center for Health Value Innovation
10. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)....,Nov.25 /PRNewswire-FirstCall/-- TheProvidenceS...itsLogistiCaresubsidiary,thenation,slargestcoordin...receivednoticeofawardfromtheStateofFloridaCommissi...idnon-emergencytransportationservicestobothMiami-D...14millioninrevenueovertheinitial18monthterm,issubj...
(Date:11/25/2009)...rovidesFinancialFlexibility,AllowingCompanytoAcces...5/PRNewswire-FirstCall/-LabopharmInc.(TSX:DDS;NASD...uitydistributionagreement(SEDA)withYAGlobalMasterS...etermsoftheagreement,YAhascommittedtoprovideupto$2...rm,sdiscretion,throughthepurchaseofnewlyissuedLabo...
(Date:11/25/2009)...change by reducing carbon dioxide and other greenh...its in addition to reducing the risk of climate ch...g to a series of six papers appearing today (Wed.,... Two University of California, Berkeley, authors o...environmental health, and Michael Jerrett, associa...
(Date:11/25/2009)... Thirty-seven million Americans are afflicte...nvasive technology for treating chronic sinus infl... Jackson, Miss. The Balloon Sinuplasty™ syst...alloon to quickly open and expand blocked sinuses....009 -- A clinically proven, minimally invasive tec...
(Date:11/25/2009)... Beginning Today through Sunday, November 29...memory foam and latex sofa bed mattress + an addit...nd a 100 night money back guarantee. Use the code ...take advantage of this special offer. , ...ns of Americans will travel from Thanksgiving thro...
Breaking Medicine News(10 mins):Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 2Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 3Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 2Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 3Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 2Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 3Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 2Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 3Health News:Providing Comfort for Holiday Guests Just Got Easier 2Health News:Providing Comfort for Holiday Guests Just Got Easier 3
...nd Specialty Pharmacy programs expand URAC,s Pharm..., Oct. 28 URAC announced that four,companies have...mail,programs under its Pharmacy Quality Managemen...am of,this scope for the pharmacy benefit manageme...
...esterol-lowering statins is associated with a stat... antigen (PSA) levels, according to a report in th...ational Cancer Institute . , Previous studies exa...ned the association between statins and PSA level....
...., Oct. 28 Dean Barkley,candidate for US Senate f...mprehensive strategy to fight HIV/AIDS in the US a...orm Coleman and other candidates from,Minnesota wi...ed to take a bold stand on this issue.", Barkley ...
...s, Oct. 28 Animal Health,International, Inc. (Nas...,release financial results for its fiscal year 200...y, November 4, 2008. Animal Health,International, ...the conference call by dialing (719) 785-1758.,Par...
...e of the ED drug delayed disease progression, rese...thDay News) -- Cialis (tadalafil), a drug used to ...reating pulmonary hypertension, researchers report... become tired, dizzy and short of breath, because ...
...Oct. 28 WellPoint, Inc. (NYSE:,WLP) announced tod...at the,following conferences:, -- Oppenheimer 19t...,at 2:00 p.m. Eastern Standard Time ("EST"); and, ...invited to listen to webcasts of the,presentations...
Other Medicine News:Health News:Four Companies Are First to Achieve Accreditation Under Two New URAC Pharmacy Quality Management(SM) Programs 2Health News:Statin use associated with reduction in prostate specific antigen levels 2Health News:Senator Dean Barkley Pledges Action on HIV/AIDS Epidemic 2Health News:Cialis May Help Ease Pulmonary Hypertension 2Health News:WellPoint Announces Appearances at Upcoming Conferences 2
(Date:11/25/2009)...ov.25/PRNewswire/--AccordingtoMillenniumResearchGr...etintelligence,thenearly$3billionUSmarketfortrauma...nextfiveyearsdespitetherecenteconomicslowdown.MRG,...hismarketwillremainhighlydynamicoverthenextfiveyea...reviouslyunderservedsegmentsofthetraumafixationmar...
(Date:11/25/2009)...,Nov.25/PRNewswire/--CempraPharmaceuticalsInc.toda...efexecutiveofficer,willpresentatthePiperJaffray21s...,2009,atTheNewYorkPalaceHotelinNewYorkCity.Dr.Fern...antibioticclinicalprogramsforthetreatmentofdrug-re...harmaceuticals ,, Foundedin2006,CempraPharmace...
(Date:11/25/2009)...PRNewswire/--Reportlinker.comannouncesthatanewmark...IntranasalDrugDelivery-USMarketTrends&Analysis...Drug-Delivery---US-Market-Trends--Analysis.html ,...anexpansionoftherapeuticapplicationsfromthedeliver...fsystemictherapeuticdrugs.Thefutureofthetechnology...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5French Physicians to Conduct 2000 Patient Study of CATANIA 28TM 29 Coronary Stent 14671 1French Physicians to Conduct 2000 Patient Study of CATANIA 28TM 29 Coronary Stent 14671 2Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 1Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 2Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 3Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 4Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 5Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 6Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 7Antibiotic Resistance Still a Major Public Health Threat 60427 1Antibiotic Resistance Still a Major Public Health Threat 60427 2Antibiotic Resistance Still a Major Public Health Threat 60427 3Antibiotic Resistance Still a Major Public Health Threat 60427 4
...aGen Corporation,(Nasdaq: CRGN ) and TopoTarget A...ay the initiation of patient dosing in a Phase I/I... histone deacetylase (HDAC),inhibitor, in combinat...tment of Acute Myeloid Leukemia (AML). The trial i...n Union. Patients under the age of 60 with relaps...
...ollment follows FDA approval of Zingo in ...CO, Calif., Aug. 28 Anesiva,Inc. (Nasdaq: ANSV )...of the,Phase 3 clinical study of Zingo(TM) (lidoca...injection system to reduce pain associated with,pe..., a fast-acting,topical, needle-free system for lo...
Other Medicine Technology:CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 2CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 3CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 4CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 5CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 6Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults 2Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults 3
Tensiobag
...ilEyes CTR is a device designed for permanent impl...ct removal surgery. It provides secondary capsular...s. The CTR is a uniplanar, 270-degree, semi-circle...ing polymethylmethacrylate (PMMA) with one manipul...
Hannum Ronguer/Grasper
Cobra Retractors
Medicine Products: